Meeting of the Advisory Committee on Blood and Tissue Safety and Availability, 57914 [2024-15566]

Download as PDF 57914 Federal Register / Vol. 89, No. 136 / Tuesday, July 16, 2024 / Notices TOTAL ESTIMATED ANNUALIZED BURDEN HOURS Number of respondents Form name Total responses Average burden per response (in hours) Total burden hours Recipient Report .................................................................................. Provider Report .................................................................................... Client Report ........................................................................................ 595 2,063 1,532 1 1 1 595 2,063 1,532 11 13 113 6,545 26,819 173,116 Total .............................................................................................. 4,190 .......................... 4,190 .................... 206,480 Maria G. Button, Director, Executive Secretariat. ACBTSA@hhs.gov. Phone: 202–795– 7608. [FR Doc. 2024–15616 Filed 7–15–24; 8:45 am] DEPARTMENT OF HEALTH AND HUMAN SERVICES Meeting of the Advisory Committee on Blood and Tissue Safety and Availability Office of the Assistant Secretary for Health, Office of the Secretary, Department of Health and Human Services. ACTION: Notice. AGENCY: The U.S. Department of Health and Human Services is hereby giving notice that the Advisory Committee on Blood and Tissue Safety and Availability (ACBTSA) will hold a meeting. The meeting will be open to the public via webcast. The committee will discuss and vote on recommendations related to tissue biovigilance. The committee will also hear presentations and updates on recent committee work related to blood and organ safety. DATES: The meeting will take place on September 4–5, 2024 from approximately 9:00 a.m.–4:00 p.m. Eastern Time (ET) on September 4th and approximately 9:00 a.m.–1:00 p.m. Eastern Time (ET) on September 5th. Meeting times are tentative and subject to change. The confirmed times and agenda items for the meeting will be posted on the ACBTSA web page at https://www.hhs.gov/oidp/advisorycommittee/blood-tissue-safetyavailability/meeting-summary/fiftyninth-acbtsa-meeting/ when this information becomes available. FOR FURTHER INFORMATION CONTACT: James Berger, Designated Federal Officer for the ACBTSA; Office of Infectious Disease and HIV/AIDS Policy, Office of the Assistant Secretary for Health, Department of Health and Human Services, Tower Building, 1101 Wootton Parkway, Rockville, MD 20852. Email: SUMMARY: VerDate Sep<11>2014 16:55 Jul 15, 2024 Jkt 262001 On the day of the meeting, please go to https:// www.hhs.gov/live/ to view the meeting. The public will have an opportunity to present their views to the ACBTSA by submitting a written public comment or providing a verbal public comment during the meeting. Comments should be pertinent to the meeting discussion. Persons who wish to provide written or verbal public comment should review instructions at https://www.hhs.gov/oidp/advisorycommittee/blood-tissue-safetyavailability/meeting-summary/fiftyninth-acbtsa-meeting/ and respond by midnight August 27, 2024, ET. Background and Authority: The ACBTSA is a discretionary Federal advisory committee and is governed by the provisions of the Federal Advisory Committee Act (FACA), Public Law 92– 463, as amended (5 U.S.C. app), which sets forth standards for the formation and use of advisory committees. The ACBTSA functions to provide advice to the Secretary through the Assistant Secretary for Health on a range of policy issues to include: (1) Identification of public health issues through surveillance of blood and tissue safety issues with national survey and data tools; (2) identification of public health issues that affect availability of blood, blood products, and tissues; (3) broad public health, ethical, and legal issues related to the safety of blood, blood products, and tissues; (4) the impact of various economic factors (e.g., product cost and supply) on safety and availability of blood, blood products, and tissues; (5) risk communications related to blood transfusion and tissue transplantation; and (6) identification of infectious disease transmission issues for blood, organs, blood stem cells and tissues. The Committee has met regularly since its establishment in 1997. SUPPLEMENTARY INFORMATION: BILLING CODE 4165–15–P khammond on DSKJM1Z7X2PROD with NOTICES Number of responses per respondent PO 00000 Frm 00072 Fmt 4703 Sfmt 4703 Dated: July 1, 2024. James J. Berger, Designated Federal Officer, Advisory Committee on Blood and Tissue Safety and Availability, Office of Infectious Disease and HIV/AIDS Policy. [FR Doc. 2024–15566 Filed 7–15–24; 8:45 am] BILLING CODE 4150–28–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Heart, Lung, and Blood Institute; Notice of Closed Meetings Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel; NHLBI Mentored Career Development KAwards. Date: August 21, 2024. Time: 11:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge I, 6705 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Zhihong Shan, Ph.D., MD, Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute National Institutes of Health, 6705 Rockledge Drive, Room 205–J Bethesda, MD 20892, (301) 827–7085, zhihong.shan@ nih.gov. Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel; Opportunities for Collaborative Research at the NIH Clinical Center (U01). Date: August 28, 2024. E:\FR\FM\16JYN1.SGM 16JYN1

Agencies

[Federal Register Volume 89, Number 136 (Tuesday, July 16, 2024)]
[Notices]
[Page 57914]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-15566]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES


Meeting of the Advisory Committee on Blood and Tissue Safety and 
Availability

AGENCY: Office of the Assistant Secretary for Health, Office of the 
Secretary, Department of Health and Human Services.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The U.S. Department of Health and Human Services is hereby 
giving notice that the Advisory Committee on Blood and Tissue Safety 
and Availability (ACBTSA) will hold a meeting. The meeting will be open 
to the public via webcast. The committee will discuss and vote on 
recommendations related to tissue biovigilance. The committee will also 
hear presentations and updates on recent committee work related to 
blood and organ safety.

DATES: The meeting will take place on September 4-5, 2024 from 
approximately 9:00 a.m.-4:00 p.m. Eastern Time (ET) on September 4th 
and approximately 9:00 a.m.-1:00 p.m. Eastern Time (ET) on September 
5th. Meeting times are tentative and subject to change. The confirmed 
times and agenda items for the meeting will be posted on the ACBTSA web 
page at https://www.hhs.gov/oidp/advisory-committee/blood-tissue-safety-availability/meeting-summary/fifty-ninth-acbtsa-meeting/ when this information becomes available.

FOR FURTHER INFORMATION CONTACT: James Berger, Designated Federal 
Officer for the ACBTSA; Office of Infectious Disease and HIV/AIDS 
Policy, Office of the Assistant Secretary for Health, Department of 
Health and Human Services, Tower Building, 1101 Wootton Parkway, 
Rockville, MD 20852. Email: [email protected]. Phone: 202-795-7608.

SUPPLEMENTARY INFORMATION: On the day of the meeting, please go to 
https://www.hhs.gov/live/ to view the meeting. The public 
will have an opportunity to present their views to the ACBTSA by 
submitting a written public comment or providing a verbal public 
comment during the meeting. Comments should be pertinent to the meeting 
discussion. Persons who wish to provide written or verbal public 
comment should review instructions at https://www.hhs.gov/oidp/advisory-committee/blood-tissue-safety-availability/meeting-summary/fifty-ninth-acbtsa-meeting/ and respond by midnight August 
27, 2024, ET.
    Background and Authority: The ACBTSA is a discretionary Federal 
advisory committee and is governed by the provisions of the Federal 
Advisory Committee Act (FACA), Public Law 92-463, as amended (5 U.S.C. 
app), which sets forth standards for the formation and use of advisory 
committees. The ACBTSA functions to provide advice to the Secretary 
through the Assistant Secretary for Health on a range of policy issues 
to include: (1) Identification of public health issues through 
surveillance of blood and tissue safety issues with national survey and 
data tools; (2) identification of public health issues that affect 
availability of blood, blood products, and tissues; (3) broad public 
health, ethical, and legal issues related to the safety of blood, blood 
products, and tissues; (4) the impact of various economic factors 
(e.g., product cost and supply) on safety and availability of blood, 
blood products, and tissues; (5) risk communications related to blood 
transfusion and tissue transplantation; and (6) identification of 
infectious disease transmission issues for blood, organs, blood stem 
cells and tissues. The Committee has met regularly since its 
establishment in 1997.

    Dated: July 1, 2024.
James J. Berger,
Designated Federal Officer, Advisory Committee on Blood and Tissue 
Safety and Availability, Office of Infectious Disease and HIV/AIDS 
Policy.
[FR Doc. 2024-15566 Filed 7-15-24; 8:45 am]
BILLING CODE 4150-28-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.